Patents by Inventor Michael C. Schneider

Michael C. Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040138156
    Abstract: Deoxyribonuclase 1-like 3 (D3) hydrolyzes lipid-complexed DNA and decreases transfection efficiency in liposomal transfection (lipofection) Systems. Accordingly, D1L3 provides a more accurate test of the efficiency of lipid/liposomal based gene therapy than current standards using deoxyribonuclease 1 (D1). Moreover, it has been found that mice with systemic lupus erythematosus (lupus) have lowered D1L3 activity. Therefore, differing therapeutic benefits may result from either the upward or downward therapeutic regulation of D1L3 activity. For example, blocking D1L3 activity enhances liposomal transfection for gene therapy, while increasing D1L3 activity may enhance destruction of pathogenic DNA, whether viral, bacterial or endogenous. Destruction of pathogenic DNA may provide treatment for lupus, or viral and oncogenic diseases.
    Type: Application
    Filed: February 26, 2003
    Publication date: July 15, 2004
    Inventors: Michael C. Schneider, Andrew Wilber